Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24944146 | 0.79 | — | — | |
| SCHEMBL21341402 | 0.76 | CFTR (0.37) | KDM4ECYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL22278010 | 0.75 | CA2 (0.38) | KDM4ECYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL12755272 | 0.71 | CDK4 (0.31) | — | |
| SCHEMBL24188636 | 0.68 | ALKBH5 (0.38) | KDM4ECYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL10212114 | 0.67 | CA2 (0.39) | KDM4ECYP1A2 | |
| SCHEMBL21024142 | 0.66 | PIK3CD (0.39) | KDM4E | |
| SCHEMBL23478882 | 0.64 | KDM4E (0.35) | KDM4ECYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23171757 | 0.62 | MAPT (0.46) | CYP1A2ATM | |
| SCHEMBL20618778 | 0.62 | KCNH2 (0.41) | CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130749-B2 | — | — | 2021-09-28 | — | — | US | disclosed |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130749-B2 | — | ROCK1, RHOA, ROCK2 | KDM4E 3164/4885CYP1A2 2822/4885CYP3A4 4485/4885 |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | KDM4E 2224/4885CYP1A2 2243/4885CYP3A4 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.